This synergy can be attributed to the inhibition of glycolysis in tumor cells and enhanced T-cell activation.48,49 These encouraging results have led to over 100 ongoing clinical studies worldwide, assessing the safety and efficacy of recombinant IFN-α in a range of hematological and solid tumors.50–52. The gene discussed is IFNA1; the disease is neoplasm.